Osivax Raises €10 Million in Series B Financing to Advance Influenza Vaccine Development
Osivax, a biopharmaceutical company focused on developing vaccines for broad-spectrum protection against highly mutating respiratory viruses, has announced the successful first close of its Series B financing, raising €10 million from both new and existing investors.
New Investor Meiji Seika Pharma Joins Osivax
The company is excited to welcome Meiji Seika Pharma Co., Ltd, a prominent Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With over 75 years of expertise, Meiji Seika Pharma, a subsidiary of the Meiji Group, brings valuable experience in vaccine development and commercialization to the table.
Funding to Support OVX836 Vaccine Development
The funds raised will support it’s continued preclinical and clinical development of OVX836, a broad-spectrum influenza vaccine candidate. The financing includes contributions from Meiji Seika Pharma, existing investors, and non-dilutive funding sources. A key focus of this investment is the ongoing Phase 2b field efficacy study (NCT05569239), designed to evaluate OVX836 against a placebo in a large cohort of 2,850 participants across multiple international sites. This study marks a critical step in advancing the science of influenza prevention beyond conventional vaccine approaches.
Strong Endorsement of Osivax’s Vision
“This funding is a strong endorsement of our technology, our team, and our vision to develop broad-spectrum influenza vaccine candidates,” said Alexandre Le Vert, CEO and Co-Founder. “We are gaining significant momentum in advancing itx’s development strategy, and we are thrilled to welcome Meiji Seika Pharma as a new investor. Their support, alongside that of our existing investors, reinforces our shared ambition to transform the prevention of respiratory infectious diseases.”
With this new funding, Osivax is well-positioned to continue its work on innovative solutions to protect against influenza and other respiratory viruses, addressing a major global health need.
About Osivax
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’s ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
For further information: https://osivax.com/
